AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
DIFFERENTIAL-EFFECTS OF LOW-MOLECULAR-WEIGHT HEPARIN AND UNFRACTIONATED HEPARIN ON CIRCULATING LEVELS OF ANTITHROMBIN AND TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - A POSSIBLE MECHANISM FOR DIFFERENCE IN THERAPEUTIC EFFICACY
Authors: HANSEN JB SANDSET PM
Citation: Jb. Hansen et Pm. Sandset, DIFFERENTIAL-EFFECTS OF LOW-MOLECULAR-WEIGHT HEPARIN AND UNFRACTIONATED HEPARIN ON CIRCULATING LEVELS OF ANTITHROMBIN AND TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - A POSSIBLE MECHANISM FOR DIFFERENCE IN THERAPEUTIC EFFICACY, Thrombosis research, 91(4), 1998, pp. 177-181
DIFFERENTIAL EFFECT OF UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN ON INTRAVASCULAR TISSUE FACTOR PATHWAY INHIBITOR - EVIDENCE FOR A DIFFERENCE IN ANTITHROMBOTIC ACTION
Authors: HANSEN JB SANDSET PM HUSEBY KR HUSEBY NE BENDZ B
Citation: Jb. Hansen et al., DIFFERENTIAL EFFECT OF UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN ON INTRAVASCULAR TISSUE FACTOR PATHWAY INHIBITOR - EVIDENCE FOR A DIFFERENCE IN ANTITHROMBOTIC ACTION, British Journal of Haematology, 101(4), 1998, pp. 638-646
CONTRIBUTION OF FACTOR-VII GENOTYPE TO ACTIVATED FVII LEVELS - DIFFERENCES IN GENOTYPE FREQUENCIES BETWEEN NORTHERN AND SOUTHERN EUROPEAN POPULATIONS
Authors: BERNARDI F ARCIERI P BERTINA RM CHIAROTTI F CORRAL J PINOTTI M PRYDZ H SAMAMA M SANDSET PM STROM R GARCIA VV MARIANI G
Citation: F. Bernardi et al., CONTRIBUTION OF FACTOR-VII GENOTYPE TO ACTIVATED FVII LEVELS - DIFFERENCES IN GENOTYPE FREQUENCIES BETWEEN NORTHERN AND SOUTHERN EUROPEAN POPULATIONS, Arteriosclerosis, thrombosis, and vascular biology, 17(11), 1997, pp. 2548-2553
DIFFERENTIAL EFFECT OF LOW-MOLECULAR-WEIGHT (LMWH) AND UNFRACTIONATED(UFH) HEPARIN ON INTRAVASCULAR TFPI - A PROPOSED MECHANISM FOR DIFFERENCE IN ANTITHROMBOTIC ACTION
Authors: HANSEN JB SANDSET PM HUSEBY KR HUSEBY NE OSTERGAARD P NORDOY A
Citation: Jb. Hansen et al., DIFFERENTIAL EFFECT OF LOW-MOLECULAR-WEIGHT (LMWH) AND UNFRACTIONATED(UFH) HEPARIN ON INTRAVASCULAR TFPI - A PROPOSED MECHANISM FOR DIFFERENCE IN ANTITHROMBOTIC ACTION, Thrombosis and haemostasis, 1997, pp. 29-29
SERUM PHOSPHOLIPIDS ARE MAJOR PREDICTORS OF FVII LEVELS
Authors: MARIANI G BERNARDI F SAMAMA R PRYDZ H GARCIA VV BERTINA RM SANDSET PM KAVLIE A ARCIERI P CIARLA MV STROM R
Citation: G. Mariani et al., SERUM PHOSPHOLIPIDS ARE MAJOR PREDICTORS OF FVII LEVELS, Thrombosis and haemostasis, 1997, pp. 50-50
EVIDENCE THAT ORAL-CONTRACEPTIVES (OC) ENHANCE PHOSPHOLIPID-DEPENDENTFACTOR-VII (FVII) ACTIVATION
Authors: MARIANI G BERNARDI F SAMAMA M PRYDZ H GARCIA VV BERTINA RM SANDSET PM CONARD J DINUCCI GD PINOTTI M CHIAROTTI F STROM R ROSENDAAL F
Citation: G. Mariani et al., EVIDENCE THAT ORAL-CONTRACEPTIVES (OC) ENHANCE PHOSPHOLIPID-DEPENDENTFACTOR-VII (FVII) ACTIVATION, Thrombosis and haemostasis, 1997, pp. 51-51
CHANGES IN SOLUBLE ENDOTHELIAL-CELL MARKERS DURING TREATMENT WITH SIMVASTATIN OR PLACEBO IN PATIENTS WITH CORONARY HEART-DISEASE
Authors: AMESEN H SELJEFLOT I SANDSET PM HJERMANN I PEDERSEN T
Citation: H. Amesen et al., CHANGES IN SOLUBLE ENDOTHELIAL-CELL MARKERS DURING TREATMENT WITH SIMVASTATIN OR PLACEBO IN PATIENTS WITH CORONARY HEART-DISEASE, Thrombosis and haemostasis, 1997, pp. 558-558
INTERACTION BETWEEN TISSUE FACTOR PATHWAY INHIBITOR (TFPI), FACTOR-VII (FVII) AND LIPIDS
Authors: SANDSET PM BERNARDI F BERTINA R GARCIA VV PRYDZ H SAMAMA M TESTA MG CHIAROTTI F MARCHETTI G CECI F MARIANI G
Citation: Pm. Sandset et al., INTERACTION BETWEEN TISSUE FACTOR PATHWAY INHIBITOR (TFPI), FACTOR-VII (FVII) AND LIPIDS, Thrombosis and haemostasis, 1997, pp. 1662-1662
STRONG CONTRIBUTION OF FVII GENOTYPES TO ACTIVATED FVII LEVELS AND DIFFERENCES IN GENOTYPE FREQUENCIES IN NORTHERN AND SOUTHERN EUROPEAN COUNTRIES
Authors: BERNARDI F BERTINA RM GARCIA VV PRYDZ H SANDSET PM CORRAL J CHIAROTTI F FERRARESE P MARIANI G
Citation: F. Bernardi et al., STRONG CONTRIBUTION OF FVII GENOTYPES TO ACTIVATED FVII LEVELS AND DIFFERENCES IN GENOTYPE FREQUENCIES IN NORTHERN AND SOUTHERN EUROPEAN COUNTRIES, Thrombosis and haemostasis, 1997, pp. 1680-1680
TISSUE FACTOR PATHWAY INHIBITOR - CLINICAL DEFICIENCY STATES
Authors: SANDSET PM BENDZ B
Citation: Pm. Sandset et B. Bendz, TISSUE FACTOR PATHWAY INHIBITOR - CLINICAL DEFICIENCY STATES, Thrombosis and haemostasis, 78(1), 1997, pp. 467-470
AN ENZYME-LINKED IMMUNOSORPTION ASSAY FOR TISSUE FACTOR PATHWAY INHIBITOR
Authors: OSTERGAARD PB BECK TC ORSTED H SVENDSEN A NORDFANG O SANDSET PM HANSEN JB
Citation: Pb. Ostergaard et al., AN ENZYME-LINKED IMMUNOSORPTION ASSAY FOR TISSUE FACTOR PATHWAY INHIBITOR, Thrombosis research, 87(5), 1997, pp. 447-459
REDUCED C4B-BINDING PROTEIN IN PREECLAMPSIA
Authors: SCHJETLEIN R HAUGEN G SANDSET PM WISLOFF F
Citation: R. Schjetlein et al., REDUCED C4B-BINDING PROTEIN IN PREECLAMPSIA, Thrombosis research, 85(2), 1997, pp. 153-158
DO ANTIPHOSPHOLIPID ANTIBODIES INFLUENCE THE INTRA-VASCULAR LEVELS OFTISSUE FACTOR PATHWAY INHIBITOR (TFPI)
Authors: JACOBSEN EM SANDSET PM WISLOFF F
Citation: Em. Jacobsen et al., DO ANTIPHOSPHOLIPID ANTIBODIES INFLUENCE THE INTRA-VASCULAR LEVELS OFTISSUE FACTOR PATHWAY INHIBITOR (TFPI), Blood, 90(10), 1997, pp. 3234-3234
PARTIAL DEPLETION OF TFPI DURING SC ADMINISTRATION OF UNFRACTIONATED HEPARIN BUT NOT WITH 2 LOW-MOLECULAR-WEIGHT HEPARINS
Authors: BENDZ B HANSEN JB ANDERSEN TO SANDSET PM
Citation: B. Bendz et al., PARTIAL DEPLETION OF TFPI DURING SC ADMINISTRATION OF UNFRACTIONATED HEPARIN BUT NOT WITH 2 LOW-MOLECULAR-WEIGHT HEPARINS, Blood, 90(10), 1997, pp. 1311-1311
DEPLETION OF INTRAVASCULAR POOLS OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) DURING REPEATED OR CONTINUOUS INTRAVENOUS-INFUSION OF HEPARIN INMAN
Authors: HANSEN JB SANDSET PM HUSEBY KR HUSEBY NE NORDOY A
Citation: Jb. Hansen et al., DEPLETION OF INTRAVASCULAR POOLS OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) DURING REPEATED OR CONTINUOUS INTRAVENOUS-INFUSION OF HEPARIN INMAN, Thrombosis and haemostasis, 76(5), 1996, pp. 703-709
TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - AN UPDATE
Authors: SANDSET PM
Citation: Pm. Sandset, TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - AN UPDATE, Haemostasis, 26, 1996, pp. 154-165
BINDING OF TISSUE FACTOR PATHWAY INHIBITOR TO CULTURED ENDOTHELIAL-CELLS - INFLUENCE OF GLYCOSAMINOGLYCANS
Authors: IVERSON N SANDSET PM ABILDGAARD U TORJESEN PA
Citation: N. Iverson et al., BINDING OF TISSUE FACTOR PATHWAY INHIBITOR TO CULTURED ENDOTHELIAL-CELLS - INFLUENCE OF GLYCOSAMINOGLYCANS, Thrombosis research, 84(4), 1996, pp. 267-278
LUPUS ANTICOAGULANT AND A FUNCTIONAL, ASSAY FOR TISSUE FACTOR PATHWAYINHIBITOR
Authors: JACOBSEN EM SANDSET PM WISLOFF F
Citation: Em. Jacobsen et al., LUPUS ANTICOAGULANT AND A FUNCTIONAL, ASSAY FOR TISSUE FACTOR PATHWAYINHIBITOR, Thrombosis research, 83(4), 1996, pp. 339-340
EFFECT OF CHOLESTEROL-LOWERING ON INTRAVASCULAR POOLS OF TFPI AND ITSANTICOAGULANT POTENTIAL IN TYPE-II HYPERLIPOPROTEINEMIA
Authors: HANSEN JB HUSEBY KR HUSEBY NE SANDSET PM HANSSEN TA NORDOY A
Citation: Jb. Hansen et al., EFFECT OF CHOLESTEROL-LOWERING ON INTRAVASCULAR POOLS OF TFPI AND ITSANTICOAGULANT POTENTIAL IN TYPE-II HYPERLIPOPROTEINEMIA, Arteriosclerosis, thrombosis, and vascular biology, 15(7), 1995, pp. 879-885
LONG-TERM ANTICOAGULANT-THERAPY IN CEREBROVASCULAR-DISEASE - DOES BLEEDING OUTWEIGH THE BENEFIT
Authors: DAHL T ABILDGAARD U SANDSET PM
Citation: T. Dahl et al., LONG-TERM ANTICOAGULANT-THERAPY IN CEREBROVASCULAR-DISEASE - DOES BLEEDING OUTWEIGH THE BENEFIT, Journal of internal medicine, 237(3), 1995, pp. 323-329
INTRAVASCULAR DISTRIBUTION OF TFPI AND ITS ANTICOAGULANT POTENTIAL AFTER CHOLESTEROL-LOWERING IN TYPE-II HYPERLIPOPROTEINEMIA
Authors: HANSEN JB HUSEBY KR HUSEBY NE SANDSET PM NORDOY A
Citation: Jb. Hansen et al., INTRAVASCULAR DISTRIBUTION OF TFPI AND ITS ANTICOAGULANT POTENTIAL AFTER CHOLESTEROL-LOWERING IN TYPE-II HYPERLIPOPROTEINEMIA, Thrombosis and haemostasis, 73(6), 1995, pp. 943-943
THROMBOTEST - CAPILLARY BLOOD METHOD FOR PROTHROMBIN TIME DETERMINATION
Authors: BRYNILDSRUD T SANDSET PM JORGENSEN M JANSON T JACOBSEN K
Citation: T. Brynildsrud et al., THROMBOTEST - CAPILLARY BLOOD METHOD FOR PROTHROMBIN TIME DETERMINATION, Thrombosis and haemostasis, 73(6), 1995, pp. 1112-1112
ACTIVATED PROTEIN-C RESISTANCE - PREVALENCE AMONG PATIENTS UNDERGOINGCORONARY-ARTERY BYPASS-SURGERY AND RELATION TO SHUNT OCCLUSIONS
Authors: ERITSLAND J GJONNES G SANDSET PM SELJEFLOT I ARNESEN H
Citation: J. Eritsland et al., ACTIVATED PROTEIN-C RESISTANCE - PREVALENCE AMONG PATIENTS UNDERGOINGCORONARY-ARTERY BYPASS-SURGERY AND RELATION TO SHUNT OCCLUSIONS, Thrombosis and haemostasis, 73(6), 1995, pp. 1374-1374
ACTIVATED PROTEIN-C RESISTANCE AND GRAFT OCCLUSION AFTER CORONARY-ARTERY BYPASS-SURGERY
Authors: ERITSLAND J GJONNES G SANDSET PM SELJEFLOT I ARNESEN H
Citation: J. Eritsland et al., ACTIVATED PROTEIN-C RESISTANCE AND GRAFT OCCLUSION AFTER CORONARY-ARTERY BYPASS-SURGERY, Thrombosis research, 79(2), 1995, pp. 223-226
TISSUE-FACTOR PATHWAY INHIBITOR AND LIPOPROTEINS - EVIDENCE FOR ASSOCIATION WITH AND REGULATION BY LDL IN HUMAN PLASMA
Authors: HANSEN JB HUSEBY NE SANDSET PM SVENSSON B LYNGMO V NORDOY A
Citation: Jb. Hansen et al., TISSUE-FACTOR PATHWAY INHIBITOR AND LIPOPROTEINS - EVIDENCE FOR ASSOCIATION WITH AND REGULATION BY LDL IN HUMAN PLASMA, Arteriosclerosis and thrombosis, 14(2), 1994, pp. 223-229
Risultati: 1-25 | 26-32